Drug Trial Radar · NCT05684705
Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100
Last checked: Nov 19, 2026Latest source record: Jan 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Sep 1, 2023
Primary completion
Oct 30, 2024
Study completion Dec 30, 2024
Sponsor
- Lead sponsor
- BioVersys AGIndustry
- Sponsor type
- Industry
- Collaborators
- CW-Research and Management GmbH
- First posted
- Jan 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100
Conditions
- Bacterial Infections
Interventions
BV100Drug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess plasma concentration of rifabutin in healthy participantsTime frame: 5 Days
- To assess epithelial lining fluid concentration of rifabutin in healthy participantsTime frame: 5 days
- To assess concentration of rifabutin in alveolar macrophages of healthy participantsTime frame: 5 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical University of Vienna
Vienna, Austria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.